OPTIC

Name: OPTIC
Brand: OPTIC

AI Native

AI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validatio

Est 2022|Raised $11M

LinkedIn 4K|Web traffic 1K|FTEs 268

Published Jul 14, 2026

01Common complaints

Enterprise compliance-first environments: If procurement requires publicly documented SOC 2/ISO and a mature public security posture, BIOPTIC may slow down deals unless it can provide private documentation.
If integrated wet-lab execution is required: BIOPTIC’s workflow assumes wet lab validation is run by the buyer or a CRO.
If broad computational chemistry breadth in one suite is needed: Tools like Schrödinger may be preferred for deep physics-based modeling and integrated informatics.
If the buyer requires abundant third-party references: Public user reviews appear scarce for BIOPTIC specifically.

- Enterprise compliance-first environments: If procurement requires publicly documented SOC 2/ISO and a mature public security posture, BIOPTIC may slow down deals unless it can provide private documentation. - If integrated wet-lab execution is required: BIOPTIC’s workflow assumes wet lab validation is run by the buyer or a CRO. - If broad computational chemistry breadth in one suite is needed: Tools like Schrödinger may be preferred for deep physics-based modeling and integrated informatics. - If the buyer requires abundant third-party references: Public user reviews appear scarce for BIOPTIC specifically.

Deal disqualifiers (poor fit)

Requirement for publicly documented SOC 2 Type II / ISO 27001 before vendor onboarding
Programs that require tightly integrated enterprise informatics, permissions, and auditability with existing platforms
Slow assay turnaround that makes rapid iterations impractical

Current limitations acknowledged implicitly or explicitly

Vendor terms include standard limitations of liability and arbitration clauses; enterprises should review contract terms carefully.
Scientific limitation: binding affinity does not guarantee functional inhibition/activation or developability (noted in peer-reviewed work).

Roadmap / future features

No detailed public roadmap with dates was identified.

Scale limitations

The platform claims very large screening scale; buyer experience will depend on:

target type and available ligand data
library choice (Enamine REAL vs internal)
assay throughput and compound availability

02Why they buy

Most validated differentiators

Peer-reviewed publication describing large-scale, rapid ligand-based screening (BIOPTIC B1) and prospective LRRK2 results
Workflow deliverables: ranked purchasable hit lists, CSV/SDF exports, and iteration plans

Claimed differentiators that need buyer validation

Vendor-reported metrics such as a ~5% hit rate and fast turnaround: these should be validated in pilot projects with defined success criteria
Agent-based scouting/diligence: assess how much automation versus manual analyst work is included and request pricing and benchmarks

03Field reports

Reality check: review scarcity / name ambiguity

Because of this, most customer evidence is:

vendor-published case studies
peer-reviewed paper (scientific validation of one component)
press releases and partner announcements

Mainstream review platforms (G2, TrustRadius, Gartner Peer Insights) do not appear to have accessible, clearly attributable review pages for BIOPTIC (bioptic.io). Searches surfaced a G2 "Optic" entry that appears to refer to a different product category (data/integration tooling) rather than the bioptic.io discovery platform. Because of this, most customer evidence is: - vendor-published case studies - peer-reviewed paper (scientific validation of one component) - press releases and partner announcements

Vendor/partner testimonial (vendor-provided language paraphrased)

A vendor press release about a collaboration with Vindur Tx includes a partner statement indicating the collaboration delivered selective ligands more quickly than expected and accelerated their research programs. This is a vendor-provided testimonial and has not been independently verified on public review platforms.

Peer-reviewed evidence (more neutral, includes limitations)

BIOPTIC’s B1 system is described in an ACS Journal of Chemical Information and Modeling paper. The paper emphasizes:

very large-scale ligand-based screening
prospective LRRK2 binder discovery from a very large enumerated virtual library
but it also explicitly notes that some biological mechanisms (binding mode / catalytic activity impact) still require experimental validation

This provides external scientific validation for the claim of fast retrieval over very large libraries, while also highlighting the experimental uncertainty common in early discovery.

BIOPTIC’s B1 system is described in an ACS Journal of Chemical Information and Modeling paper. The paper emphasizes: - very large-scale ligand-based screening - prospective LRRK2 binder discovery from a very large enumerated virtual library - but it also explicitly notes that some biological mechanisms (binding mode / catalytic activity impact) still require experimental validation This provides external scientific validation for the claim of fast retrieval over very large libraries, while also highlighting the experimental uncertainty common in early discovery.

Community discussion

There is very limited authentic community discussion about BIOPTIC (bioptic.io) specifically on Reddit or Hacker News.

Reddit content for "bioptic" largely refers to low-vision driving aids rather than the drug discovery platform.
Hacker News did not surface direct product discussions for BIOPTIC; a thread mentioning Andrey Doronichev was in an unrelated context.

Implication: The lack of community chatter may indicate (a) early-stage or limited user base, (b) private, sales-led deployments, or (c) brand-name ambiguity complicating discoverability.

There is very limited authentic community discussion about BIOPTIC (bioptic.io) specifically on Reddit or Hacker News. - Reddit content for "bioptic" largely refers to low-vision driving aids rather than the drug discovery platform. - Hacker News did not surface direct product discussions for BIOPTIC; a thread mentioning Andrey Doronichev was in an unrelated context. Implication: The lack of community chatter may indicate (a) early-stage or limited user base, (b) private, sales-led deployments, or (c) brand-name ambiguity complicating discoverability.

Negative reviews / complaints

Verified low-rating reviews were not found on major public platforms for BIOPTIC. The negative aspects section below focuses on plausible, evidence-linked risk factors and limitations that recur in AI drug discovery and in BIOPTIC’s disclosures.

Case Study A — TNIK (Obesity / fibrosis / anti-aging)

BIOPTIC-published case study (Oct 2, 2024) reports:

chemical space: Enamine REAL 39B
hit rate (standard potency threshold): a moderate hit rate
most potent hit: sub-micromolar potency
models: B1 and B2

Critical evaluation:

Metrics are reported by the vendor and lack independent replication details (assay protocols, reproducibility, counter-screens).
Claims about TNIK as a target are directional and do not alone validate clinical feasibility.

BIOPTIC-published case study (Oct 2, 2024) reports: - chemical space: Enamine REAL 39B - hit rate (standard potency threshold): a moderate hit rate - most potent hit: sub-micromolar potency - models: B1 and B2 Critical evaluation: - Metrics are reported by the vendor and lack independent replication details (assay protocols, reproducibility, counter-screens). - Claims about TNIK as a target are directional and do not alone validate clinical feasibility.

Case Study B — VEGFR3 (FLT4) selectivity program

BIOPTIC case study (Mar 1, 2025) reports:

hit rate (standard potency threshold): a low single-digit hit rate
most potent hit: low-micromolar potency
selectivity vs closest targets: tens-fold selectivity versus closely related VEGFR targets

Critical evaluation:

Selectivity data, if robust, is meaningful; however, assay conditions and kinase panel breadth are not fully public.
Program co-ownership with partner Oncobox is mentioned; ownership and IP terms are not public.

BIOPTIC case study (Mar 1, 2025) reports: - hit rate (standard potency threshold): a low single-digit hit rate - most potent hit: low-micromolar potency - selectivity vs closest targets: tens-fold selectivity versus closely related VEGFR targets Critical evaluation: - Selectivity data, if robust, is meaningful; however, assay conditions and kinase panel breadth are not fully public. - Program co-ownership with partner Oncobox is mentioned; ownership and IP terms are not public.

Peer-reviewed case — LRRK2 (Parkinson’s)

The JCIM paper reports:

prospective application to LRRK2 with low-nanomolar binding affinity reported
search over a very large Enamine REAL virtual space
a CPU-only retrieval system searching a pre-indexed database in minutes

Critical evaluation:

This is the strongest independent validation surfaced: publication in a peer-reviewed journal.
Translating binders into development candidates remains a long path (ADMET, selectivity, efficacy, etc.).

The JCIM paper reports: - prospective application to LRRK2 with low-nanomolar binding affinity reported - search over a very large Enamine REAL virtual space - a CPU-only retrieval system searching a pre-indexed database in minutes Critical evaluation: - This is the strongest independent validation surfaced: publication in a peer-reviewed journal. - Translating binders into development candidates remains a long path (ADMET, selectivity, efficacy, etc.).

04Best fit

Company sizes

Biotechs: small-to-mid sized biotechs (early through growth stage), especially those without large internal screening infrastructure
Mid-size pharma / divisions: groups able to fund moderate-to-high-range discovery sprints and that prioritize speed
Venture studios / BD teams: where the Agents capability aligns with scouting and diligence needs

Industries / verticals

Small-molecule therapeutic discovery (including oncology, metabolic disease, neurodegeneration)

Roles/personas

Decision makers: VP Discovery, Head of Biology/Chemistry, Head of Translational/Preclinical, BD/licensing leads
End users: computational chemists, medicinal chemists, project leads, external CRO managers

Qualification criteria (good fit)

The buyer has a clear target and can run fast assays (or has a CRO lined up)
The buyer can purchase/synthesize compounds from large vendor catalogs
The buyer values speed and breadth of chemical space exploration over building a bespoke in-house modeling stack

05The pitch

What the product does (core value proposition)

OPTIC (Optic, Inc.) markets BIOPTIC, an AI-driven platform intended to accelerate early small-molecule drug discovery. Primary capabilities include:

large-scale virtual screening over make-on-demand libraries (including major commercial make-on-demand collections)
producing a ranked, purchasable hit list with predicted potency/ADMET flags and ordering links
supporting iterative cycles ("screen → test → refine") in collaboration with a customer’s in-house lab or CRO

From BIOPTIC’s platform description, the product is presented as a workflow that can accept either a protein sequence (no structure) or known ligands and return prioritized compounds. The vendor states hit lists are often delivered within a short timeframe, depending on context and target.

OPTIC (Optic, Inc.) markets BIOPTIC, an AI-driven platform intended to accelerate early small-molecule drug discovery. Primary capabilities include: - large-scale virtual screening over make-on-demand libraries (including major commercial make-on-demand collections) - producing a ranked, purchasable hit list with predicted potency/ADMET flags and ordering links - supporting iterative cycles ("screen → test → refine") in collaboration with a customer’s in-house lab or CRO From BIOPTIC’s platform description, the product is presented as a workflow that can accept either a protein sequence (no structure) or known ligands and return prioritized compounds. The vendor states hit lists are often delivered within a short timeframe, depending on context and target.

Target market and positioning

BIOPTIC is targeted at:

biotech and pharma R&D teams conducting hit identification and early hit-to-lead work
venture creation, BD, and licensing teams that require scouting/diligence tooling (the vendor also offers separate "Agents" functionality)

The vendor positions OPTIC as both:

a large-scale screening engine (B1/B2/B3 models), and
an agent-based competitive/asset intelligence capability (marketed as pharma-trained AI agents).

BIOPTIC is targeted at: - biotech and pharma R&D teams conducting hit identification and early hit-to-lead work - venture creation, BD, and licensing teams that require scouting/diligence tooling (the vendor also offers separate "Agents" functionality) The vendor positions OPTIC as both: 1) a large-scale screening engine (B1/B2/B3 models), and 2) an agent-based competitive/asset intelligence capability (marketed as pharma-trained AI agents).

Get a comprehensive analysis of OPTIC including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →